Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis
Identifieur interne : 003E34 ( Pmc/Curation ); précédent : 003E33; suivant : 003E35Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis
Auteurs : Su-Xia Guo ; Zhen-Yu Yang ; Ru-Xing Wang ; Ying Yang ; Hua-Ming Cao ; Tao ZhangSource :
- Experimental and Therapeutic Medicine [ 1792-0981 ] ; 2012.
Abstract
Studies have shown that a C1019T polymorphism of the gene encoding the gap junction protein connexin37 is associated with coronary artery disease (CAD). The aim of the present study was to explore the association between the C1019T polymorphism in the connexin37 gene and CAD patients with in-stent restenosis (ISR). A total of 532 patients who had undergone coronary stenting and coronary angiography at least three months after the procedure were divided according to a clinical diagnosis standard into two groups which were ISR (n=67) and no in-stent restenosis (NISR; n=465) groups. A further 501 healthy individuals were controls. The subjects were genotyped by DNA sequencing. The results demonstrated the following: i) connexin37 gene 1019 sites in the population were distributed by polymorphism into three genetic types (CC, TC and TT types). The distribution frequency of the healthy control, ISR and NISR groups conformed to the Hardy-Weinberg genetic balance rule; ii) in comparison with the healthy controls, the frequency of the connexin37 C allele was higher in the CAD patients (57.05% vs. 41.32%; OR, 1.89; 95% CI, 1.58–2.25; P<0.01). The frequency of the C carriers (CC+TC) was 65.47% in the healthy controls, vs. 79.32% in CAD patients (P<0.01). The CAD risk was significantly increased in the carriers of the C allele (CC+TC) compared with TT homozygotes (OR, 2.03; 95% CI, 1.53–2.80; P<0.01). Stratified analysis demonstrated that a significant difference existed in the frequency of C carriers between the male CAD patients and healthy controls (79.63% vs. 72.45%; OR, 1.48; 95% CI, 1.06–2.09, P=0.02), as well as in the female CAD patients (78.00% vs. 51.50%; OR, 3.34; 95% CI, 1.90–5.86; P<0.01). In the female and male CAD patients, the frequency of the connexin37 C allele was higher than in the healthy controls (male: χ2=12.67, P<0.01; female: χ2=50.20, P<0.01); iii) compared with the NISR group, the frequencies of the connexin37 C allele and C carriers (CC+TC) were significantly higher in the ISR group (frequency of C allele: 72.39% vs. 54.84%; P<0.01; frequency of C carriers: 89.55% vs. 77.85%; P=0.03). Compared with TT homozygotes, the restenosis risk was significantly increased in the carriers of the C allele (CC+TC; OR, 2.44; 95% CI, 1.08–5.50). Subsequent stratified analysis revealed that the frequency of the C allele was significantly higher in the male ISR group than in the male NISR group (78.57% vs. 52.66%; OR, 3.30; 95% CI, 2.05–5.29; P<0.01). The restenosis risk was ∼four-fold higher in the C carriers (CC+TC) than in the TT homozygotes (OR, 3.74; 95% CI, 1.32–10.64). However in the female population, there was no difference in the ISR risk between the carriers of the C allele (CC+TC) and the TT homozygotes (P=0.70). In summary, the C allele of the connexin37 gene is not only is associated with the susceptibility to CAD, but also associated with restenosis following coronary stenting in the population studied herein, particularly the male population.
Url:
DOI: 10.3892/etm.2012.852
PubMed: 23403905
PubMed Central: 3570167
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003E35
Links to Exploration step
PMC:3570167Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis</title><author><name sortKey="Guo, Su Xia" sort="Guo, Su Xia" uniqKey="Guo S" first="Su-Xia" last="Guo">Su-Xia Guo</name></author><author><name sortKey="Yang, Zhen Yu" sort="Yang, Zhen Yu" uniqKey="Yang Z" first="Zhen-Yu" last="Yang">Zhen-Yu Yang</name></author><author><name sortKey="Wang, Ru Xing" sort="Wang, Ru Xing" uniqKey="Wang R" first="Ru-Xing" last="Wang">Ru-Xing Wang</name></author><author><name sortKey="Yang, Ying" sort="Yang, Ying" uniqKey="Yang Y" first="Ying" last="Yang">Ying Yang</name></author><author><name sortKey="Cao, Hua Ming" sort="Cao, Hua Ming" uniqKey="Cao H" first="Hua-Ming" last="Cao">Hua-Ming Cao</name></author><author><name sortKey="Zhang, Tao" sort="Zhang, Tao" uniqKey="Zhang T" first="Tao" last="Zhang">Tao Zhang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23403905</idno><idno type="pmc">3570167</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570167</idno><idno type="RBID">PMC:3570167</idno><idno type="doi">10.3892/etm.2012.852</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">003E35</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003E35</idno><idno type="wicri:Area/Pmc/Curation">003E34</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003E34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis</title><author><name sortKey="Guo, Su Xia" sort="Guo, Su Xia" uniqKey="Guo S" first="Su-Xia" last="Guo">Su-Xia Guo</name></author><author><name sortKey="Yang, Zhen Yu" sort="Yang, Zhen Yu" uniqKey="Yang Z" first="Zhen-Yu" last="Yang">Zhen-Yu Yang</name></author><author><name sortKey="Wang, Ru Xing" sort="Wang, Ru Xing" uniqKey="Wang R" first="Ru-Xing" last="Wang">Ru-Xing Wang</name></author><author><name sortKey="Yang, Ying" sort="Yang, Ying" uniqKey="Yang Y" first="Ying" last="Yang">Ying Yang</name></author><author><name sortKey="Cao, Hua Ming" sort="Cao, Hua Ming" uniqKey="Cao H" first="Hua-Ming" last="Cao">Hua-Ming Cao</name></author><author><name sortKey="Zhang, Tao" sort="Zhang, Tao" uniqKey="Zhang T" first="Tao" last="Zhang">Tao Zhang</name></author></analytic><series><title level="j">Experimental and Therapeutic Medicine</title><idno type="ISSN">1792-0981</idno><idno type="eISSN">1792-1015</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Studies have shown that a C1019T polymorphism of the gene encoding the gap junction protein connexin37 is associated with coronary artery disease (CAD). The aim of the present study was to explore the association between the C1019T polymorphism in the connexin37 gene and CAD patients with in-stent restenosis (ISR). A total of 532 patients who had undergone coronary stenting and coronary angiography at least three months after the procedure were divided according to a clinical diagnosis standard into two groups which were ISR (n=67) and no in-stent restenosis (NISR; n=465) groups. A further 501 healthy individuals were controls. The subjects were genotyped by DNA sequencing. The results demonstrated the following: i) connexin37 gene 1019 sites in the population were distributed by polymorphism into three genetic types (CC, TC and TT types). The distribution frequency of the healthy control, ISR and NISR groups conformed to the Hardy-Weinberg genetic balance rule; ii) in comparison with the healthy controls, the frequency of the connexin37 C allele was higher in the CAD patients (57.05% vs. 41.32%; OR, 1.89; 95% CI, 1.58–2.25; P<0.01). The frequency of the C carriers (CC+TC) was 65.47% in the healthy controls, vs. 79.32% in CAD patients (P<0.01). The CAD risk was significantly increased in the carriers of the C allele (CC+TC) compared with TT homozygotes (OR, 2.03; 95% CI, 1.53–2.80; P<0.01). Stratified analysis demonstrated that a significant difference existed in the frequency of C carriers between the male CAD patients and healthy controls (79.63% vs. 72.45%; OR, 1.48; 95% CI, 1.06–2.09, P=0.02), as well as in the female CAD patients (78.00% vs. 51.50%; OR, 3.34; 95% CI, 1.90–5.86; P<0.01). In the female and male CAD patients, the frequency of the connexin37 C allele was higher than in the healthy controls (male: χ<sup>2</sup>=12.67, P<0.01; female: χ<sup>2</sup>=50.20, P<0.01); iii) compared with the NISR group, the frequencies of the connexin37 C allele and C carriers (CC+TC) were significantly higher in the ISR group (frequency of C allele: 72.39% vs. 54.84%; P<0.01; frequency of C carriers: 89.55% vs. 77.85%; P=0.03). Compared with TT homozygotes, the restenosis risk was significantly increased in the carriers of the C allele (CC+TC; OR, 2.44; 95% CI, 1.08–5.50). Subsequent stratified analysis revealed that the frequency of the C allele was significantly higher in the male ISR group than in the male NISR group (78.57% vs. 52.66%; OR, 3.30; 95% CI, 2.05–5.29; P<0.01). The restenosis risk was ∼four-fold higher in the C carriers (CC+TC) than in the TT homozygotes (OR, 3.74; 95% CI, 1.32–10.64). However in the female population, there was no difference in the ISR risk between the carriers of the C allele (CC+TC) and the TT homozygotes (P=0.70). In summary, the C allele of the connexin37 gene is not only is associated with the susceptibility to CAD, but also associated with restenosis following coronary stenting in the population studied herein, particularly the male population.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Serruys, Pw" uniqKey="Serruys P">PW Serruys</name></author><author><name sortKey="Kutryk, Mj" uniqKey="Kutryk M">MJ Kutryk</name></author><author><name sortKey="Ong, At" uniqKey="Ong A">AT Ong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, G" uniqKey="Cheng G">G Cheng</name></author><author><name sortKey="Wang, H" uniqKey="Wang H">H Wang</name></author><author><name sortKey="Chen, M" uniqKey="Chen M">M Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yan, Kp" uniqKey="Yan K">KP Yan</name></author><author><name sortKey="Guo, Y" uniqKey="Guo Y">Y Guo</name></author><author><name sortKey="Xing, Z" uniqKey="Xing Z">Z Xing</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marfella, R" uniqKey="Marfella R">R Marfella</name></author><author><name sortKey="Sasso, Fc" uniqKey="Sasso F">FC Sasso</name></author><author><name sortKey="Siniscalchi, M" uniqKey="Siniscalchi M">M Siniscalchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kastrati, A" uniqKey="Kastrati A">A Kastrati</name></author><author><name sortKey="Schomig, A" uniqKey="Schomig A">A Schömig</name></author><author><name sortKey="Elezi, S" uniqKey="Elezi S">S Elezi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weintraub, Ws" uniqKey="Weintraub W">WS Weintraub</name></author><author><name sortKey="Kosinski, As" uniqKey="Kosinski A">AS Kosinski</name></author><author><name sortKey="Brown, Cl" uniqKey="Brown C">CL Brown</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saez, Jc" uniqKey="Saez J">JC Saez</name></author><author><name sortKey="Berthoud, Vm" uniqKey="Berthoud V">VM Berthoud</name></author><author><name sortKey="Branes, Mc" uniqKey="Branes M">MC Branes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fang, Js" uniqKey="Fang J">JS Fang</name></author><author><name sortKey="Angelov, Sn" uniqKey="Angelov S">SN Angelov</name></author><author><name sortKey="Simon, Am" uniqKey="Simon A">AM Simon</name></author><author><name sortKey="Burt, Jm" uniqKey="Burt J">JM Burt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kanady, Jd" uniqKey="Kanady J">JD Kanady</name></author><author><name sortKey="Dellinger, Mt" uniqKey="Dellinger M">MT Dellinger</name></author><author><name sortKey="Munger, Sj" uniqKey="Munger S">SJ Munger</name></author><author><name sortKey="Witte, Mh" uniqKey="Witte M">MH Witte</name></author><author><name sortKey="Simon, Am" uniqKey="Simon A">AM Simon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morel, S" uniqKey="Morel S">S Morel</name></author><author><name sortKey="Kwak, Br" uniqKey="Kwak B">BR Kwak</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yeh, Hi" uniqKey="Yeh H">HI Yeh</name></author><author><name sortKey="Chang, Hm" uniqKey="Chang H">HM Chang</name></author><author><name sortKey="Lu, Ww" uniqKey="Lu W">WW Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pfenniger, A" uniqKey="Pfenniger A">A Pfenniger</name></author><author><name sortKey="Wong, C" uniqKey="Wong C">C Wong</name></author><author><name sortKey="Sutter, E" uniqKey="Sutter E">E Sutter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fang, Js" uniqKey="Fang J">JS Fang</name></author><author><name sortKey="Angelov, Sn" uniqKey="Angelov S">SN Angelov</name></author><author><name sortKey="Simon, Am" uniqKey="Simon A">AM Simon</name></author><author><name sortKey="Burt, Jm" uniqKey="Burt J">JM Burt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boerma, M" uniqKey="Boerma M">M Boerma</name></author><author><name sortKey="Forsberg, L" uniqKey="Forsberg L">L Forsberg</name></author><author><name sortKey="Van Zeij, L" uniqKey="Van Zeij L">L Van Zeij</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yeh, Hl" uniqKey="Yeh H">HL Yeh</name></author><author><name sortKey="Chou, Y" uniqKey="Chou Y">Y Chou</name></author><author><name sortKey="Liu, Hf" uniqKey="Liu H">HF Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Han, Yl" uniqKey="Han Y">YL Han</name></author><author><name sortKey="Xi, Sy" uniqKey="Xi S">SY Xi</name></author><author><name sortKey="Zhang, Xl" uniqKey="Zhang X">XL Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, Cw" uniqKey="Wong C">CW Wong</name></author><author><name sortKey="Christen, T" uniqKey="Christen T">T Christen</name></author><author><name sortKey="Pfenniger, A" uniqKey="Pfenniger A">A Pfenniger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamada, Y" uniqKey="Yamada Y">Y Yamada</name></author><author><name sortKey="Izawa, H" uniqKey="Izawa H">H Izawa</name></author><author><name sortKey="Ichiwara, S" uniqKey="Ichiwara S">S Ichiwara</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Listi, F" uniqKey="Listi F">F Listi</name></author><author><name sortKey="Candore, G" uniqKey="Candore G">G Candore</name></author><author><name sortKey="Lio, D" uniqKey="Lio D">D Lio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jm" uniqKey="Chan J">JM Chan</name></author><author><name sortKey="Rhee, Jw" uniqKey="Rhee J">JW Rhee</name></author><author><name sortKey="Drum, Cl" uniqKey="Drum C">CL Drum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Egan, Cg" uniqKey="Egan C">CG Egan</name></author><author><name sortKey="Caporali, F" uniqKey="Caporali F">F Caporali</name></author><author><name sortKey="Huqi, Af" uniqKey="Huqi A">AF Huqi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stiefel, P" uniqKey="Stiefel P">P Stiefel</name></author><author><name sortKey="Moreno Luna, R" uniqKey="Moreno Luna R">R Moreno-Luna</name></author><author><name sortKey="Vallejo Vaz, Aj" uniqKey="Vallejo Vaz A">AJ Vallejo-Vaz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leu, Hb" uniqKey="Leu H">HB Leu</name></author><author><name sortKey="Chung, Cm" uniqKey="Chung C">CM Chung</name></author><author><name sortKey="Chuang, Sy" uniqKey="Chuang S">SY Chuang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Puljung, Mc" uniqKey="Puljung M">MC Puljung</name></author><author><name sortKey="Berthoud, Vm" uniqKey="Berthoud V">VM Berthoud</name></author><author><name sortKey="Beyer, Ec" uniqKey="Beyer E">EC Beyer</name></author><author><name sortKey="Hanck, Da" uniqKey="Hanck D">DA Hanck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cai, Wj" uniqKey="Cai W">WJ Cai</name></author><author><name sortKey="Koltai, S" uniqKey="Koltai S">S Koltai</name></author><author><name sortKey="Kocsis, E" uniqKey="Kocsis E">E Kocsis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong, Cw" uniqKey="Wong C">CW Wong</name></author><author><name sortKey="Christen, T" uniqKey="Christen T">T Christen</name></author><author><name sortKey="Roth, I" uniqKey="Roth I">I Roth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Collings, A" uniqKey="Collings A">A Collings</name></author><author><name sortKey="Raitakari, Ot" uniqKey="Raitakari O">OT Raitakari</name></author><author><name sortKey="Juonala, M" uniqKey="Juonala M">M Juonala</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Ther Med</journal-id><journal-id journal-id-type="iso-abbrev">Exp Ther Med</journal-id><journal-id journal-id-type="publisher-id">ETM</journal-id><journal-title-group><journal-title>Experimental and Therapeutic Medicine</journal-title></journal-title-group><issn pub-type="ppub">1792-0981</issn><issn pub-type="epub">1792-1015</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23403905</article-id><article-id pub-id-type="pmc">3570167</article-id><article-id pub-id-type="doi">10.3892/etm.2012.852</article-id><article-id pub-id-type="publisher-id">etm-05-02-0539</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>GUO</surname><given-names>SU-XIA</given-names></name><xref ref-type="corresp" rid="c1-etm-05-02-0539"></xref></contrib><contrib contrib-type="author"><name><surname>YANG</surname><given-names>ZHEN-YU</given-names></name></contrib><contrib contrib-type="author"><name><surname>WANG</surname><given-names>RU-XING</given-names></name></contrib><contrib contrib-type="author"><name><surname>YANG</surname><given-names>YING</given-names></name></contrib><contrib contrib-type="author"><name><surname>CAO</surname><given-names>HUA-MING</given-names></name></contrib><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>TAO</given-names></name></contrib><aff id="af1-etm-05-02-0539">Department of Cardiology, The Affiliated People’s Hospital of Nanjing Medical University in Wuxi and People’s Hospital of Wuxi City, Jiangsu, Wuxi 214023,<country>P.R. China</country></aff></contrib-group><author-notes><corresp id="c1-etm-05-02-0539">Correspondence to: Dr Su-Xia Guo or Dr Zhen-Yu Yang, Department of Cardiology, The Affiliated People’s Hospital of Nanjing Medical University in Wuxi and People’s Hospital of Wuxi City, Wuxi, 299 Qingyang Road, Jiangsu 214023, P.R. China, E-mail: <email>suxiaguocn@163.com</email>, E-mail: <email>zhenyuyang3746@126.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>05</day><month>12</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>12</month><year>2012</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on the
<volume>5</volume><issue>2</issue><fpage>539</fpage><lpage>544</lpage><history><date date-type="received"><day>16</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2013, Spandidos Publications</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><abstract><p>Studies have shown that a C1019T polymorphism of the gene encoding the gap junction protein connexin37 is associated with coronary artery disease (CAD). The aim of the present study was to explore the association between the C1019T polymorphism in the connexin37 gene and CAD patients with in-stent restenosis (ISR). A total of 532 patients who had undergone coronary stenting and coronary angiography at least three months after the procedure were divided according to a clinical diagnosis standard into two groups which were ISR (n=67) and no in-stent restenosis (NISR; n=465) groups. A further 501 healthy individuals were controls. The subjects were genotyped by DNA sequencing. The results demonstrated the following: i) connexin37 gene 1019 sites in the population were distributed by polymorphism into three genetic types (CC, TC and TT types). The distribution frequency of the healthy control, ISR and NISR groups conformed to the Hardy-Weinberg genetic balance rule; ii) in comparison with the healthy controls, the frequency of the connexin37 C allele was higher in the CAD patients (57.05% vs. 41.32%; OR, 1.89; 95% CI, 1.58–2.25; P<0.01). The frequency of the C carriers (CC+TC) was 65.47% in the healthy controls, vs. 79.32% in CAD patients (P<0.01). The CAD risk was significantly increased in the carriers of the C allele (CC+TC) compared with TT homozygotes (OR, 2.03; 95% CI, 1.53–2.80; P<0.01). Stratified analysis demonstrated that a significant difference existed in the frequency of C carriers between the male CAD patients and healthy controls (79.63% vs. 72.45%; OR, 1.48; 95% CI, 1.06–2.09, P=0.02), as well as in the female CAD patients (78.00% vs. 51.50%; OR, 3.34; 95% CI, 1.90–5.86; P<0.01). In the female and male CAD patients, the frequency of the connexin37 C allele was higher than in the healthy controls (male: χ<sup>2</sup>=12.67, P<0.01; female: χ<sup>2</sup>=50.20, P<0.01); iii) compared with the NISR group, the frequencies of the connexin37 C allele and C carriers (CC+TC) were significantly higher in the ISR group (frequency of C allele: 72.39% vs. 54.84%; P<0.01; frequency of C carriers: 89.55% vs. 77.85%; P=0.03). Compared with TT homozygotes, the restenosis risk was significantly increased in the carriers of the C allele (CC+TC; OR, 2.44; 95% CI, 1.08–5.50). Subsequent stratified analysis revealed that the frequency of the C allele was significantly higher in the male ISR group than in the male NISR group (78.57% vs. 52.66%; OR, 3.30; 95% CI, 2.05–5.29; P<0.01). The restenosis risk was ∼four-fold higher in the C carriers (CC+TC) than in the TT homozygotes (OR, 3.74; 95% CI, 1.32–10.64). However in the female population, there was no difference in the ISR risk between the carriers of the C allele (CC+TC) and the TT homozygotes (P=0.70). In summary, the C allele of the connexin37 gene is not only is associated with the susceptibility to CAD, but also associated with restenosis following coronary stenting in the population studied herein, particularly the male population.</p></abstract><kwd-group><kwd>coronary heart disease</kwd><kwd>in-stent restenosis</kwd><kwd>connexin37</kwd><kwd>gene polymorphism</kwd></kwd-group></article-meta></front><floats-group><fig id="f1-etm-05-02-0539" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Gene sequencing diagram. (A) CC type. (B) TT type. (C) TC type.</p></caption><graphic xlink:href="ETM-05-02-0539-g00"></graphic></fig><table-wrap id="t1-etm-05-02-0539" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of the clinical data of patients among the three groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Factor</th><th align="center" valign="middle" rowspan="1" colspan="1">Control group (n=501)</th><th align="center" valign="middle" rowspan="1" colspan="1">NISR group (n=465)</th><th align="center" valign="middle" rowspan="1" colspan="1">ISR group (n=67)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">62.07±8.51</td><td align="center" valign="top" rowspan="1" colspan="1">62.64±12.00</td><td align="center" valign="top" rowspan="1" colspan="1">59.18±8.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">334/167</td><td align="center" valign="top" rowspan="1" colspan="1">376/89</td><td align="center" valign="top" rowspan="1" colspan="1">56/11<xref rid="tfn2-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref><xref rid="tfn3-etm-05-02-0539" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI</td><td align="center" valign="top" rowspan="1" colspan="1">24.48±3.25</td><td align="center" valign="top" rowspan="1" colspan="1">24.53±3.36</td><td align="center" valign="top" rowspan="1" colspan="1">24.49±3.41</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">130±21</td><td align="center" valign="top" rowspan="1" colspan="1">132±18</td><td align="center" valign="top" rowspan="1" colspan="1">138±25</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" valign="top" rowspan="1" colspan="1">84±16</td><td align="center" valign="top" rowspan="1" colspan="1">90±20</td><td align="center" valign="top" rowspan="1" colspan="1">92±24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting blood sugar (mmol/l)</td><td align="center" valign="top" rowspan="1" colspan="1">5.26±0.98</td><td align="center" valign="top" rowspan="1" colspan="1">5.73±1.00</td><td align="center" valign="top" rowspan="1" colspan="1">5.72±0.82</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine (mg/dl)</td><td align="center" valign="top" rowspan="1" colspan="1">85.11±21.63</td><td align="center" valign="top" rowspan="1" colspan="1">87.33±15.07</td><td align="center" valign="top" rowspan="1" colspan="1">81.57±16.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">History</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Smoking (yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">378/123</td><td align="center" valign="top" rowspan="1" colspan="1">417/48</td><td align="center" valign="top" rowspan="1" colspan="1">58/9<xref rid="tfn2-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref><xref rid="tfn3-etm-05-02-0539" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Drinking (yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">346/155</td><td align="center" valign="top" rowspan="1" colspan="1">356/109</td><td align="center" valign="top" rowspan="1" colspan="1">49/18<xref rid="tfn2-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref><xref rid="tfn3-etm-05-02-0539" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stent</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Diameter (mm)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">2.98±0.67</td><td align="center" valign="top" rowspan="1" colspan="1">2.79±0.87<xref rid="tfn3-etm-05-02-0539" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Length (mm)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">23.46±8.59</td><td align="center" valign="top" rowspan="1" colspan="1">24.16±9.23<xref rid="tfn3-etm-05-02-0539" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Stent release pressure (atm)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">14.23±4.68</td><td align="center" valign="top" rowspan="1" colspan="1">15.11±3.42<xref rid="tfn3-etm-05-02-0539" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Aspirin (yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">465/2</td><td align="center" valign="top" rowspan="1" colspan="1">67/0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Clopidogrel (yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">465/0</td><td align="center" valign="top" rowspan="1" colspan="1">67/0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> β-blockers (yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">457/8</td><td align="center" valign="top" rowspan="1" colspan="1">65/2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> ACEI/ARB(yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">445/20</td><td align="center" valign="top" rowspan="1" colspan="1">64/3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> Statins (yes/no)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">463/2</td><td align="center" valign="top" rowspan="1" colspan="1">66/1</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-etm-05-02-0539"><p>Data expressed as mean ± SD.</p></fn><fn id="tfn2-etm-05-02-0539"><label>a</label><p>P<005 compared among the three groups.</p></fn><fn id="tfn3-etm-05-02-0539"><label>b</label><p>P<0.05 compared with the NISR group. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; ISR, in-stent restenosis; NISR, no in-stent restenosis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-etm-05-02-0539" orientation="portrait" position="float"><label>Table II.</label><caption><p>Analysis of gene polymorphism test results in the CAD and control groups (%).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1">Genotype
<hr></hr></th><th colspan="2" align="center" valign="middle" rowspan="1">Allele
<hr></hr></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CC</th><th align="center" valign="middle" rowspan="1" colspan="1">CT</th><th align="center" valign="middle" rowspan="1" colspan="1">TT</th><th align="center" valign="middle" rowspan="1" colspan="1">CC+TC</th><th align="center" valign="middle" rowspan="1" colspan="1">C</th><th align="center" valign="middle" rowspan="1" colspan="1">T</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CAD group (n=532)</td><td align="center" valign="top" rowspan="1" colspan="1">185 (34.77)</td><td align="center" valign="top" rowspan="1" colspan="1">237 (44.55)</td><td align="center" valign="top" rowspan="1" colspan="1">110 (20.68)</td><td align="center" valign="top" rowspan="1" colspan="1">422 (79.32)</td><td align="center" valign="top" rowspan="1" colspan="1">607 (57.05)</td><td align="center" valign="top" rowspan="1" colspan="1">457 (42.95)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group (n=501)</td><td align="center" valign="top" rowspan="1" colspan="1">86 (17.16)</td><td align="center" valign="top" rowspan="1" colspan="1">242 (48.30)</td><td align="center" valign="top" rowspan="1" colspan="1">173 (34.53)</td><td align="center" valign="top" rowspan="1" colspan="1">328 (65.47)</td><td align="center" valign="top" rowspan="1" colspan="1">414 (41.32)</td><td align="center" valign="top" rowspan="1" colspan="1">588 (58.68)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> χ<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">49.36</td><td align="center" valign="top" rowspan="1" colspan="1">24.90</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">51.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> P-value</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td><td align="center" valign="top" rowspan="1" colspan="1"><0.01<xref rid="tfn4-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> OR (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">2.03 (1.53–2.8)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">1.89 (1.58–2.25)</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="tfn4-etm-05-02-0539"><label>a</label><p>compared with TT. CAD, coronary artery disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-etm-05-02-0539" orientation="portrait" position="float"><label>Table III.</label><caption><p>Analysis of gene polymorphism test results in the ISR and NISR groups (%).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1">Genotype
<hr></hr></th><th colspan="2" align="center" valign="middle" rowspan="1">Allele
<hr></hr></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CC</th><th align="center" valign="middle" rowspan="1" colspan="1">CT</th><th align="center" valign="middle" rowspan="1" colspan="1">TT</th><th align="center" valign="middle" rowspan="1" colspan="1">CC+TC</th><th align="center" valign="middle" rowspan="1" colspan="1">C</th><th align="center" valign="middle" rowspan="1" colspan="1">T</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ISR group (n=67)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (55.22)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (34.33)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (10.45)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (89.55)</td><td align="center" valign="top" rowspan="1" colspan="1">97 (72.39)</td><td align="center" valign="top" rowspan="1" colspan="1">37 (27.61)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NISR group (n=465)</td><td align="center" valign="top" rowspan="1" colspan="1">148 (31.83)</td><td align="center" valign="top" rowspan="1" colspan="1">214 (46.02)</td><td align="center" valign="top" rowspan="1" colspan="1">103 (22.15)</td><td align="center" valign="top" rowspan="1" colspan="1">362 (77.85)</td><td align="center" valign="top" rowspan="1" colspan="1">510 (54.84)</td><td align="center" valign="top" rowspan="1" colspan="1">420 (45.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> χ<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">14.89</td><td align="center" valign="top" rowspan="1" colspan="1">4.89</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">14.72</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> P-value</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.027<xref rid="tfn5-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> OR (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">2.44 (1.08–5.50)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">2.16 (1.45–3.22)</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="tfn5-etm-05-02-0539"><label>a</label><p>compared with TT. ISR, in-stent restenosis; NISR, no in-stent restenosis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-etm-05-02-0539" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Connexin37 gene C1019T polymorphism distribution (%) in males in the CAD and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1">Genotype
<hr></hr></th><th colspan="2" align="center" valign="middle" rowspan="1">Allele
<hr></hr></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CC</th><th align="center" valign="middle" rowspan="1" colspan="1">CT</th><th align="center" valign="middle" rowspan="1" colspan="1">TT</th><th align="center" valign="middle" rowspan="1" colspan="1">CC+TC</th><th align="center" valign="middle" rowspan="1" colspan="1">C</th><th align="center" valign="middle" rowspan="1" colspan="1">T</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CAD group (n=432)</td><td align="center" valign="top" rowspan="1" colspan="1">140 (32.41)</td><td align="center" valign="top" rowspan="1" colspan="1">204 (47.22)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (20.37)</td><td align="center" valign="top" rowspan="1" colspan="1">344 (79.63)</td><td align="center" valign="top" rowspan="1" colspan="1">484 (56.02)</td><td align="center" valign="top" rowspan="1" colspan="1">380 (43.98)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group (n=334)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (21.26)</td><td align="center" valign="top" rowspan="1" colspan="1">171 (51.20)</td><td align="center" valign="top" rowspan="1" colspan="1">92 (27.54)</td><td align="center" valign="top" rowspan="1" colspan="1">242 (72.45)</td><td align="center" valign="top" rowspan="1" colspan="1">313 (46.86)</td><td align="center" valign="top" rowspan="1" colspan="1">355 (53.14)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> χ<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">14.52</td><td align="center" valign="top" rowspan="1" colspan="1">5.39</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">12.67</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> P-value</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td align="center" valign="top" rowspan="1" colspan="1">0.02<xref rid="tfn6-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> OR (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1.48 (1.06–2.09)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">1.45 (1.18–1.77)</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="tfn6-etm-05-02-0539"><label>a</label><p>compared with TT. CAD, coronary artery disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-etm-05-02-0539" orientation="portrait" position="float"><label>Table V.</label><caption><p>Connexin37 gene C1019T polymorphism distribution (%) in females in the CAD and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1">Genotype
<hr></hr></th><th colspan="2" align="center" valign="middle" rowspan="1">Allele
<hr></hr></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CC</th><th align="center" valign="middle" rowspan="1" colspan="1">CT</th><th align="center" valign="middle" rowspan="1" colspan="1">TT</th><th align="center" valign="middle" rowspan="1" colspan="1">CC+TC</th><th align="center" valign="middle" rowspan="1" colspan="1">C</th><th align="center" valign="middle" rowspan="1" colspan="1">T</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">CAD group (n=100)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (45.00)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (33.00)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (22.00)</td><td align="center" valign="top" rowspan="1" colspan="1">78 (78.00)</td><td align="center" valign="top" rowspan="1" colspan="1">123 (61.50)</td><td align="center" valign="top" rowspan="1" colspan="1">77 (38.50)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Control group (n=167)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (8.98)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (42.51)</td><td align="center" valign="top" rowspan="1" colspan="1">81 (48.50)</td><td align="center" valign="top" rowspan="1" colspan="1">86 (51.50)</td><td align="center" valign="top" rowspan="1" colspan="1">101 (30.24)</td><td align="center" valign="top" rowspan="1" colspan="1">233 (67.76)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> χ<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">48.95</td><td align="center" valign="top" rowspan="1" colspan="1">18.54</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">50.20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> P-value</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td><td align="center" valign="top" rowspan="1" colspan="1"><0.01<xref rid="tfn7-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> OR (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">3.34 (1.90–5.86)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">3.69 (2.55–5.33)</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="tfn7-etm-05-02-0539"><label>a</label><p>compared with TT. CAD, coronary artery disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-etm-05-02-0539" orientation="portrait" position="float"><label>Table VI.</label><caption><p>Connexin37 gene C1019T polymorphism distribution (%) in males in the ISR and NISR groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1">Genotype
<hr></hr></th><th colspan="2" align="center" valign="middle" rowspan="1">Allele
<hr></hr></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CC</th><th align="center" valign="middle" rowspan="1" colspan="1">CT</th><th align="center" valign="middle" rowspan="1" colspan="1">TT</th><th align="center" valign="middle" rowspan="1" colspan="1">CC+TC</th><th align="center" valign="middle" rowspan="1" colspan="1">C</th><th align="center" valign="middle" rowspan="1" colspan="1">T</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ISR group (n=56)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (64.29)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (28.57)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (7.14)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (92.86)</td><td align="center" valign="top" rowspan="1" colspan="1">88 (78.57)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (21.43)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NISR group (n=376)</td><td align="center" valign="top" rowspan="1" colspan="1">104 (27.66)</td><td align="center" valign="top" rowspan="1" colspan="1">188 (50.00)</td><td align="center" valign="top" rowspan="1" colspan="1">84 (22.34)</td><td align="center" valign="top" rowspan="1" colspan="1">292 (77.66)</td><td align="center" valign="top" rowspan="1" colspan="1">396 (52.66)</td><td align="center" valign="top" rowspan="1" colspan="1">356 (47.34)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> χ<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">30.44</td><td align="center" valign="top" rowspan="1" colspan="1">6.94</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">26.57</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> P-value</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.008<xref rid="tfn8-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"><0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> OR (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">3.74 (1.32–10.64)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">3.30 (2.05–5.29)</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="tfn8-etm-05-02-0539"><label>a</label><p>compared with TT. ISR, in-stent restenosis; NISR, no in-stent restenosis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7-etm-05-02-0539" orientation="portrait" position="float"><label>Table VII.</label><caption><p>Connexin37 gene C1019T polymorphism distribution (%) in females in the ISR and NISR groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"></th><th colspan="4" align="center" valign="middle" rowspan="1">Genotype
<hr></hr></th><th colspan="2" align="center" valign="middle" rowspan="1">Allele
<hr></hr></th></tr><tr><th align="left" valign="middle" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" rowspan="1" colspan="1">CC</th><th align="center" valign="middle" rowspan="1" colspan="1">CT</th><th align="center" valign="middle" rowspan="1" colspan="1">TT</th><th align="center" valign="middle" rowspan="1" colspan="1">CC+TC</th><th align="center" valign="middle" rowspan="1" colspan="1">C</th><th align="center" valign="middle" rowspan="1" colspan="1">T</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ISR group (n=11)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (9.09)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (63.64)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (27.27)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (72.73)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (40.91)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (59.09)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NISR group (n=89)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (49.44)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (29.21)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (21.35)</td><td align="center" valign="top" rowspan="1" colspan="1">70 (78.65)</td><td align="center" valign="top" rowspan="1" colspan="1">114 (64.04)</td><td align="center" valign="top" rowspan="1" colspan="1">64 (35.96)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> χ<sup>2</sup></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">7.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">4.43</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> P-value</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.027</td><td align="center" valign="top" rowspan="1" colspan="1">0.655<xref rid="tfn9-etm-05-02-0539" ref-type="table-fn"><sup>a</sup></xref></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"> OR (95% CI)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">0.72 (0.18–3.00)</td><td align="center" valign="top" rowspan="1" colspan="1"></td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.16–0.96)</td></tr></tbody></table><table-wrap-foot><fn><p>Note:</p></fn><fn id="tfn9-etm-05-02-0539"><label>a</label><p>compared with TT. ISR, in-stent restenosis; NISR, no in-stent restenosis.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 003E34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:3570167
|texte= Association between C1019T polymorphism of the connexin37 gene and coronary heart disease in patients with in-stent restenosis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:23403905" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |